PT  - JOURNAL ARTICLE
AU  - Edouard, S.
AU  - Colson, P.
AU  - Melenotte, C.
AU  - De Pinto, F.
AU  - Thomas, L.
AU  - La Scola, B.
AU  - Million, M.
AU  - Tissot-Dupont, H.
AU  - Gautret, P.
AU  - Stein, A.
AU  - Brouqui, P.
AU  - Parola, P.
AU  - Lagier, J.-C.
AU  - Raoult, D.
AU  - Drancourt, M.
TI  - Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France
AID  - 10.1101/2020.05.05.20092064
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.05.20092064
4099  - http://medrxiv.org/content/early/2020/05/12/2020.05.05.20092064.short
4100  - http://medrxiv.org/content/early/2020/05/12/2020.05.05.20092064.full
AB  - An indirect immunofluorescent assay was developed in order to assess the serological status of 888 RT-PCR-confirmed COVID-19 patients (1,302 serum samples) and controls in Marseille, France. Incorporating an inactivated clinical SARS CoV-2 isolate as the antigen, the specificity of the assay was measured as 100% for IgA titre ≥ 1:200; 98.6% for IgM titre ≥ 1:200; and 96.3% for IgG titre ≥ 1:100 after testing a series of negative controls as well as 150 serums collected from patients with non-SARS-CoV-2 Coronavirus infection, non-Coronavirus pneumonia and infections known to elicit false-positive serology. Seroprevalence was then measured at 3% before a five-day evolution up to 47% after more than 15 days of evolution. We observed that the seroprevalence as well as the titre of specific antibodies were both significantly higher in patients with a poor clinical outcome than in patients with a favourable evolution. These data, which have to be integrated into the ongoing understanding of the immunological phase of the infection, suggest that serotherapy may not be a therapeutic option in patients with severe COVID-19 infection. The IFA assay reported here is useful for monitoring SARS-CoV-2 exposure at the individual and population levels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by ANR-15-CE36-0004-01 and by ANR “Investissements d’Avenir” Méditerranée Infection 10-IAHU-03. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript